Yumanity Therapeutics Email Format

BiotechnologyMassachusetts, United States11-50 Employees

Yumanity Therapeutics is a Boston-based biotechnology research company focused on discovering and developing therapies for neurodegenerative diseases driven by protein misfolding. It aims to deliver disease-modifying treatments that address the underlying cellular pathologies, rather than merely treating symptoms, with a pipeline focused on Alzheimer’s disease, Parkinson’s disease, and ALS. Founded in December 2014 by Susan Lindquist and Tony Coles, the company has developed proprietary platforms to identify new disease targets and chemical leads.

Yumanity positions itself to work with pharmaceutical developers and research organizations seeking disease-modifying options for central nervous system disorders by addressing the root protein misfolding biology. The company reports ongoing efforts to advance a Parkinson’s-targeted lead compound and to identify additional compounds for Alzheimer’s and ALS. In 2022, Yumanity entered into an Asset Purchase Agreement with Janssen Pharmaceutica NV, reflecting external partnerships to advance its programs.

Get verified Yumanity Therapeutics emails free

Company overview Employee directory